{"entity":{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","aka":[],"tldr":"Led CONVERT, which set the radiotherapy schedule for limited-stage small-cell lung cancer.","summary":"Corinne Faivre-Finn was chief investigator of CONVERT, the international trial that compared twice-daily and once-daily thoracic radiotherapy in limited-stage SCLC and confirmed twice-daily 45 Gy as the standard. She co-leads studies of radiotherapy-immunotherapy combinations in the PACIFIC and ADRIATIC era and the Christie's thoracic radiotherapy research group.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faivre-Finn%20C%5BAuthor%5D%20small-cell%20radiotherapy"}],"tags":["radiotherapy","sclc"],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["convert","adriatic"],"people":[],"bottlenecks":[],"keyPapers":["paper-adriatic-nejm-2024"],"journals":["journal-of-thoracic-oncology"],"dependsOn":[],"notes":[],"role":"Professor of Thoracic Radiation Oncology, University of Manchester and The Christie","institutionId":"the-christie","specialisms":["Small-cell lung cancer radiotherapy","Thoracic radiotherapy","Radiotherapy-immunotherapy combinations","Real-world data"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faivre-Finn%20C%5BAuthor%5D%20small-cell%20radiotherapy"}],"papers":[{"title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30318-2"},{"title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC: an update from the PACIFIC trial","journal":"Journal of Thoracic Oncology","year":2021,"doi":"10.1016/j.jtho.2020.12.015"},{"title":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2404873","doi":"10.1056/NEJMoa2404873"}],"orcid":"0000-0001-5617-9781"},"route":"/people/corinne-faivre-finn/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"institution":[{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/"}],"trial":[{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/"},{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/"}],"paper":[{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/"}],"journal":[{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/"}],"person":[{"id":"alastair-greystoke","kind":"person","name":"Alastair Greystoke","route":"/people/alastair-greystoke/"},{"id":"sanjay-popat","kind":"person","name":"Sanjay Popat","route":"/people/sanjay-popat/"}]}}